NCT03330405 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03330405
Title	Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Recruitment	Terminated
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Pfizer
Indications	progesterone-receptor positive breast cancer transitional cell carcinoma ovarian cancer prostate cancer estrogen-receptor positive breast cancer Advanced Solid Tumor lung non-small cell carcinoma triple-receptor negative breast cancer
Therapies	Avelumab + Talazoparib
Age Groups:	adult \| senior
Covered Countries	USA \| HUN \| GBR \| DNK \| CAN \| BEL \| AUS

NCT03330405
Clinical Trial Detail